Article
Biochemistry & Molecular Biology
Zsofia Kutil, Marat Meleshin, Petra Baranova, Barbora Havlinova, Mike Schutkowski, Cyril Barinka
Summary: In this study, the researchers designed and synthesized a peptide library to investigate the substrate specificity of Class IIa histone deacetylases (HDACs). The results showed a strong preference for aromatic acids flanking the central modified lysine, while positively charged residues and proline were disfavored at specific positions. The chemical nature of amino acid residues N-terminally to the modified lysine had a greater impact on substrate recognition than residues located C-terminally.
Article
Oncology
Ai Zhuang, Xiang Gu, Tongxin Ge, Shaoyun Wang, Shengfang Ge, Peiwei Chai, Renbing Jia, Xianqun Fan
Summary: This study demonstrates that histone deacetylation inhibitors (HDACis) can inhibit the growth of ocular melanoma cells by regulating N6-methyladenine (m(6)A) RNA modification. Further investigation reveals that HDACis restore the histone acetylation level of METTL14, promoting the expression of FAT4 and exerting anti-cancer effects.
CANCER COMMUNICATIONS
(2023)
Article
Oncology
Shanshan Deng, Souvik Banerjee, Hao Chen, Satyanarayana Pochampally, Yuxi Wang, Mi-Kyung Yun, Stephen W. White, Keyur Parmar, Bernd Meibohm, Kelli L. Hartman, Zhongzhi Wu, Duane D. Miller, Wei Li
Summary: This study reports a novel inhibitor, SB226, which shows great promise for cancer therapy. Through extensive preclinical studies and in vitro/in vivo experiments, it was confirmed that SB226 has high affinity for tubulin dimers, exhibits anti-proliferative activities, inhibits tumor growth, induces apoptosis, and shows no obvious toxicity.
Article
Biochemistry & Molecular Biology
Anuradha Kumari, Shweta S. Prassanawar, Dulal Panda
Summary: Indibulin, a microtubule-depolymerizing agent, shows minimal neurotoxicity and is less cytotoxic towards differentiated neuronal cells. It binds to beta-tubulin isotypes differently and has a lower affinity to beta-III tubulin. Depletion of beta-III tubulin increases the toxicity of indibulin and colchicine, while vinblastine is unaffected. Indibulin inhibits colchicine binding to tubulin and is a colchicine-site binder.
ACS CHEMICAL NEUROSCIENCE
(2023)
Article
Biochemistry & Molecular Biology
Hongyi Zhou, Huabo Su, Weiqin Chen
Summary: The study reveals that neddylation plays a crucial role in myoblast differentiation by regulating class IIa and III histone deacetylases. This provides new insights into the mechanisms of muscle disease and regeneration, highlighting the importance of neddylation in controlling the myogenic program.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Nutrition & Dietetics
Susie Youn, Dean T. Eurich, Michael McCall, John Walker, Michael Smylie, Michael B. Sawyer
Summary: This study found that sarcopenia and myosteatosis are associated with decreased survival in patients with resected stage III melanoma.
CLINICAL NUTRITION
(2022)
Article
Gastroenterology & Hepatology
Akihisa Kato, Itaru Naitoh, Aya Naiki-Ito, Kazuki Hayashi, Fumihiro Okumura, Yasuaki Fujita, Hitoshi Sano, Yuji Nishi, Katsuyuki Miyabe, Tadahisa Inoue, Atsuyuki Hirano, Hiroki Takada, Michihiro Yoshida, Yasuki Hori, Makoto Natsume, Hiroyuki Kato, Satoru Takahashi, Hiromi Kataoka
Summary: TUBB3 might predict the response to GnP, but it is not a prognostic factor for overall survival, helping in the selection of an optimized first-line chemotherapy regimen for unresectable PDAC.
Review
Pharmacology & Pharmacy
I. Anestopoulos, S. Kyriakou, V. Tragkola, I. Paraskevaidis, E. Tzika, M. Mitsiogianni, M. V. Deligiorgi, G. Petrakis, D. T. Trafalis, S. Botaitis, A. Giatromanolaki, M. I. Koukourakis, R. Franco, A. Pappa, M. I. Panayiotidis
Summary: This review article discusses current therapeutic options in melanoma treatment, focusing on distinct epigenetic alterations and how specific drug compounds can reverse these changes. Abnormal epigenetic mechanisms have been found to be associated with the onset, progression, and drug resistance of melanoma.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pathology
Akiyoshi Hoshino, Chika Nakayama, Shi-Xu Jiang, Yasutaka Sakurai, Takuya Kato, Yoshiko Numata, Atsuko Umezawa, Masaaki Ichinoe, Yoshiki Murakumo
Summary: The expression of REV7 is associated with disease progression in malignant melanoma, with its depletion suppressing cell proliferation and migration while affecting signaling pathways activation.
PATHOLOGY INTERNATIONAL
(2022)
Article
Oncology
Stefanie Meyer, Diana Handke, Anja Mueller, Katharina Biehl, Markus Kreuz, Juergen Bukur, Ulrike Koehl, Maria-Filothei Lazaridou, Mark Berneburg, Andre Steven, Chiara Massa, Barbara Seliger
Summary: Limited knowledge exists about the molecular processes controlling HLA class II APM components in melanoma. This study found heterogeneous basal expression of HLA class II antigens and components in melanoma cells is caused by distinct molecular mechanisms and has clinical relevance.
Article
Medicine, Research & Experimental
Mandy Schott, Melanie Kappelmann-Fenzl, Stefan Fischer, Maite G. Fernandez-Barrena, Antonio Pineda-Lucena, Matias A. avila, Silke Kuphal, Anja-Katrin Bosserhoff
Summary: The tumor suppressive function of CYLD has been identified in melanoma, but the precise molecular mechanism remains unclear. This study generated a novel melanoma mouse model and found that CYLD plays a role in chromatin structure formation through histone methylation. These findings reveal a new role of CYLD in melanoma progression.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Nilabhra Mitra, Sanghamitra Dey
Summary: The roles and regulatory mechanisms of plant sirtuins, including OsSRT1, have been elucidated in this study. OsSRT1 is capable of deacetylating H3K9Ac as well as other lysine residues in histones H3 and H4. Moreover, it exhibits dual enzymatic activity of mono ADP ribosylation and deacetylation, and is involved in the DNA damage repair pathway. Therefore, OsSRT1 plays a crucial role in plant responses to biotic and abiotic stresses.
Article
Multidisciplinary Sciences
Manuel Croix, Guenaelle Levallet, Nicolas Richard, Claire Bracquemart, Taha Tagmouti, Anne Dompmartin, Diane Kottler, Jean Matthieu L'Orphelin
Summary: The therapeutic approach for metastatic melanoma depends on the performance status, metastatic sites, and BRAF V600 status. BRAF mutations and NRAS mutations are usually mutually exclusive, but some rare BRAF mutations are preferentially associated with a NRAS mutation, leading to cell proliferation. A patient with metastatic melanoma harboring a rare class III BRAF mutation associated with NRAS mutation experienced treatment failure. Next Generation Sequencing (NGS) can help identify all mutations early and guide treatment decisions.
Article
Chemistry, Medicinal
Mohammed O. O. Altonsy, George X. X. Song-Zhao, Mahmoud M. M. Mostafa, Paule Regine Mydlarski
Summary: The development of innovative therapies in the past decade, such as targeting the BRAF/MAPK kinase pathway and the PD-1 pathway, has significantly improved the treatment of metastatic melanoma. However, not all patients respond to these therapies, emphasizing the need for further research on melanoma's pathophysiology. This study found that increasing Kruppel-like factor 9 (KLF9) levels sensitizes malignant melanoma to paclitaxel, a chemotherapeutic agent when first-line treatments fail. These findings suggest that KLF9 could be a potential target for improving the chemotherapeutic response in melanoma.
Article
Biochemistry & Molecular Biology
Qingping Zhang, Binchu Xu, Fulan Hu, Xianjin Chen, Xinmin Liu, Qinghua Zhang, You Zuo
Summary: TNC acts as an oncogenic factor in glioma by modulating the PI3K/AKT signaling pathway, promoting cancer cell proliferation and stemness, while inhibiting apoptosis and chemosensitivity.
JOURNAL OF MOLECULAR NEUROSCIENCE
(2021)